Clinical trials: Bipolar Disorder I
Depressive Disorder, Major, Bipolar Disorder
Psychiatric Genotype/Phenotype Project Repository
The purpose of this project is to obtain DNA, brain imaging data, other biological samples (e.g., urine, serum), and a comprehensive clinical assessment on patients with schizophrenia and other psychotic disorders, bipolar…
- Conditions
- Depressive Disorder, Major, Bipolar Disorder, Psychotic Disorders
- Trial name
- PGPP (NCT00762866)
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Bipolar Disorder
Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)
The purpose of this study is to assess the safety and tolerability of ziprasidone during a long-term open label study in children and adolescents (ages 10-17) with Bipolar I Disorder (Manic or Mixed).
- Trial name
- NCT01124877
- Testing
- ziprasidone oral capsules
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Bipolar I Disorder
A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents
The purpose of the study is to evaluate the long-term safety profile of the Investigational Medication Depakote ER in the treatment of Bipolar I Disorder, manic or mixed episode, in children and adolescents ages 10-17.
- Trial name
- NCT00195780
- Testing
- Divalproex Sodium (Depakote ER)
- Where
- 29 sites in United States
- Volunteers
- 227 people
- Sponsor
- Abbott
Bipolar I Disorder
Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder
The purpose of the research is to study brain structure, function and chemistry of patients with bipolar disorder who are receiving lithium, an FDA-approved treatment for bipolar mania, in order to better understand who benefits…
- Trial name
- LAMBS/LADS (NCT00608075)
- Testing
- lithium
- Where
- United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati
Schizophrenia, Bipolar I Disorder
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
The purpose of this study is to evaluate the long-term safety and tolerability of cariprazine in the treatment of pediatric participants with schizophrenia, bipolar I disorder, or autism spectrum disorder (ASD) and to establish…
- Conditions
- Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD)
- Trial name
- 3070 Ped OLE (NCT04578756)
- Testing
- Cariprazine Flexible Dose
- Where
- 42 sites in United States, Puerto Rico
- Volunteers
- 310 people
- Sponsor
- AbbVie
Bipolar Depression
A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression
The main goal of this study is to help answer the following research question(s) and not to treat the child's illness. Can this study drug make children with bipolar depression feel better? Does this study drug work better than a…
- Trial name
- NCT00844857
- Testing
- Olanzapine Fluoxetine Combination (OFC)
- Where
- 7 sites in United States, Russia
- Volunteers
- 291 people
- Sponsor
- Eli Lilly and Company
Bipolar I Disorder
A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder
In this study, quetiapine is being tested for the possible treatment of bipolar I disorder with an acute depressive episode in children and adolescents.
- Trial name
- NCT00232414
- Testing
- Quetiapine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Cincinnati
Depression, Bipolar Affective Disorder
Effectiveness of Digital Cognitive Behavioral Therapy for the Treatment of Depression: a Real-world Study
The project proposes to develop a digital product based on cognitive behavioral therapy for the assisted treatment of depression.
- Conditions
- Depression, Bipolar Affective Disorder, Schizophenia Disorder, Psychiatric &Amp;or Mood Disorder
- Trial name
- NCT06831435
- Testing
- a digital product based on CBT
- Where
- China
- Volunteers
- 325 people
- Sponsor
- Peking University
Bipolar I Disorder
Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder
This was an extension study consisting of 2 parts. In Part I, all participants received open-label treatment with BIA 2-093 900 mg once daily for 2 weeks.
- Trial name
- NCT01825837
- Testing
- BIA 2-093 1800 mg once daily [Group 1 (Part II)], BIA 2-093 900 mg once daily [Group 2 (Part II)], BIA 2-093 300 mg once daily [Group 3 (Part II)]
- Volunteers
- 104 people
- Sponsor
- Bial - Portela C S.A.
Bipolar Disorder
Open-Label Study of N-Acetylcysteine in Children and Adolescents 5-17 With Bipolar Spectrum Disorders
Children between the ages of 5-17 years old who have or display symptoms of emotional dysregulation (explosiveness, mood swings, irritability, and/or violent behavior) are invited to participate in a 12-week research study to…
- Trial name
- NCT02357290
- Testing
- Open-label Treatment with N-Acetylcysteine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
First Episode Psychosis, Schizophrenia, Childhood
Early Psychosis Intervention - Spreading Evidence-based Treatment
Implementation of 'NAVIGATE' in Ontario aims to help youth and emerging adults suffering from a first episode of psychosis. Although Ontario already has early psychosis intervention programs, the team's recent work has identified…
- Conditions
- First Episode Psychosis, Schizophrenia, Childhood, Psychosis, Schizophrenia
- Trial name
- EPI-SET (NCT03919760)
- Testing
- NAVIGATE, Treatment as Usual
- Where
- 6 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Centre for Addiction and Mental Health